Clinical Trial Update: Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating tacrolimus and mycophenolate mofetil as post-grafting immunosuppression for graft-versus-host disease; current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Prograf (Tacrolimus)

Snippet

Sponsor: Colorado Blood Cancer Institute | Conditions: Graft Versus Host Disease | Phase 3 | Status: UNKNOWN